Written Question·Department of Health and Social Care·UIN 100314
Prostate Cancer: Screening
Tabled: 16 December 2025
Answered: 14 January 2026
Question
Jim Shannon
Democratic Unionist Party — Strangford
To ask the Secretary of State for Health and Social Care, what assessment he has been made of the adequacy of national production capacity for PSMA radiotracers in the context of projected clinical demand for prostate cancer diagnosis.
Answer
Ashley DaltonProstate-specific membrane antigen (PSMA) radiotracers are commissioned for use as part of PET-CT prostate cancer imaging, as set out in the published clinical commissioning policy. Access to PET-CT, as with any healthcare service, is closely monitored.